Table 1.

Patients’ characteristics who received NY-ESO-1-TCR-gene transduced lymphocyte transfer

Cohort	Patient no	Age at entry (years)	Sex	HLA-A type	Disease	NY-ESO-1 expression (IHC %)	Tumor lesions at entry
1 (5×108 cell dose)	1	Late 60s	F	02:01	Breast cancer	5–<25	Lung, lymph node
	2	Early 40s	F	02:01	Synovial sarcoma	≥75	Lung
	3	Early 70s	M	02:01	Malignant salivary tumor	<5	Primary lesion at parotid gland
2 (5×109 cell dose)	7	Late 40s	M	02:01	Synovial sarcoma	≥75	Soft tissue at femoral area, lung
	9	Early 60s	M	02:01	Melanoma	≥75	Skin, liver, peritonium
	8	Early 70s	M	02:01	Synovial sarcoma	≥75	Chest wall, soft tissue at inguinal area, bone
	14	Late 60s	F	02:06	Ovarian cancer	25–<50	Lymph node
	16	Late 20s	M	02:06	Synovial sarcoma	≥75	Lung
	15	Late 40s	F	02:01	Myxoid liposarcoma	50–<75	Retroperitonium

IHC, immunohistochemistry; TCR, T cell receptor.